Questions and Controversies in the Clinical Application of Tyrosine Kinase Inhibitors to Treat Patients with Radioiodine-Refractory Differentiated Thyroid Carcinoma: Expert Perspectives

Notwithstanding regulatory approval of lenvatinib and sorafenib to treat radioiodine-refractory differentiated thyroid carcinoma (RAI-R DTC), important questions and controversies persist regarding this use of these tyrosine kinase inhibitors (TKIs). RAI-R DTC experts from German tertiary referral c...

Descripción completa

Detalles Bibliográficos
Autores principales: Verburg, Frederik A., Amthauer, Holger, Binse, Ina, Brink, Ingo, Buck, Andreas, Darr, Andreas, Dierks, Christine, Koch, Christine, König, Ute, Kreissl, Michael C., Luster, Markus, Reuter, Christoph, Scheidhauer, Klemens, Willenberg, Holger Sven, Zielke, Andreas, Schott, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7932822/
https://www.ncbi.nlm.nih.gov/pubmed/33652491
http://dx.doi.org/10.1055/a-1380-4154

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7932822/
https://www.ncbi.nlm.nih.gov/pubmed/33652491
http://dx.doi.org/10.1055/a-1380-4154

Ejemplares similares